Results 51 to 60 of about 2,385 (197)

Analysis of the Financial Impact of Using Cangrelor on the Safety and Efficacy Outcomes in Patients Undergoing Percutaneous Coronary Intervention in Whom Oral Therapy with P2Y12 Inhibitors is Not Feasible or Desirable, in Spain

ClinicoEconomics and Outcomes Research, 2021
Irene Lizano-Díez,1 Silvia Paz Ruiz2 1Ferrer, Barcelona, Spain; 2SmartWorking4U SLU, Benicàssim, SpainCorrespondence: Irene Lizano-DíezFerrer, Av Diagonal 549, Barcelona 08029, SpainTel +34 93 600 37 00Email ilizano@ferrer.comPurpose:
Lizano-Díez I, Paz Ruiz S
doaj  

Unveiling the Microvasculature: The Index of Microcirculatory Resistance and Its Expanding Role in Cardiovascular Care

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Index of microcirculatory resistance (IMR) is a cutting‐edge, wire‐based tool that advances the capability assessment of coronary microvascular function. By utilizing distal coronary pressure and mean transit time under maximal hyperemia, IMR delivers consistent, reproducible insights into the microvasculature's dynamic health.
Joanna Sohn, Matthew A. Soderstrom, Ariana Ramirez, John‐Henry Dean, Raj Shah, Debanshu Roy, Kenneth Stone, Ariel Vinas, Bryan Ramsey, Charles Lin, Robert Chilton   +10 more
wiley   +1 more source

Impact of Reticulated Platelets on the Antiplatelet Effect of the Intravenous P2Y12-Receptor Inhibitor Cangrelor [PDF]

, 2018
Background Reticulated platelets are associated with impaired antiplatelet response to irreversibly acting P2Y12-receptor inhibitors. However, the impact of reticluated platelets (RP) on the reversibly acting injectable P2Y12-receptor ...
Christian Valina, Nikolaus Löffelhardt, Valina, Christian Marc, Kambis Mashayekhi, Mashayekhi, Kambis, Hochholzer, Willibald, Willibald Hochholzer, Christian Stratz, Neumann, Franz-Josef, Nührenberg, Thomas G., Dietmar Trenk, Thomas Nührenberg, Miroslaw Ferenc, Franz-Josef Neumann, Löffelhardt, Nikolaus, Ferenc, Miroslaw, Trenk, Dietmar, Stratz, Christian   +17 more
core   +1 more source

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

Российский кардиологический журнал, 2021
2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment ...
J.-P. Collet, H. Thiele, E. Barbato, O. Barthélémy, J. Bauersachs, D. L. Bhatt, P. Dendale, M. Dorobantu, T. Edvardsen, T. Folliguet, Ch. P. Gale, M. Gilard, A. Jobs, P. Jüni, E. Lambrinou, B. S. Lewis, Ju. Mehilli, E. Meliga, B. Merkely, O. Mueller, M. Roffi, F. H. Rutten, D. Sibbing, G. C.M. Siontis   +23 more
doaj   +1 more source

The Arranged Marriage of Cangrelor and Bivalirudin

JACC: Cardiovascular Interventions, 2015
Bivalirudin and cangrelor are 2 intravenous drugs, 1 for anticoagulation and the other for antiplatelet therapy, with a rapid onset of action, thus in theory perfectly adapted to percutaneous coronary intervention (PCI) that requires simultaneous thrombin and platelet inhibition.
Montalescot, Gilles, Helft, Gérard
openaire   +2 more sources

The potential for biased signalling in the P2Y receptor family of GPCRs

British Journal of Pharmacology, EarlyView.
The purinergic receptor family is primarily activated by nucleotides, and contains members of both the G protein coupled‐receptor (GPCR) superfamily (P1 and P2Y) and ligand‐gated ion channels (P2X). The P2Y receptors are widely expressed in the human body, and given the ubiquitous nature of nucleotides, purinergic signalling is involved with a plethora
Claudia M. Sisk, Simon Pitchford, Graham Ladds   +2 more
wiley   +1 more source

The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX [PDF]

, 2015
Aims To assess whether the use of the femoral or radial approach for percutaneous coronary intervention (PCI) interacted with the efficacy and safety of cangrelor, an intravenous P2Y12 inhibitor, in CHAMPION PHOENIX. Methods and results A total of 11 145
Steg, PG, Deliargyris, EN, Hamm, CW, Blankenship, JC, Gibson, CM, Stone, GW, Price, MJ, Bhatt, DL, Harrington, RA, White, HD, Prats, J, Gutierrez, JA, Mahaffey, K, Genereux, P   +13 more
core   +1 more source

Figure 5: Inhibition of ADP-Induced Platelet Aggregation With Cangrelor [PDF]

, 2019
(A to D) Representative tracings of adenosine diphosphate (ADP) (20 μM)-induced aggregation of platelets isolated from neonatal and pediatric patients with congenital heart disease or healthy adult volunteers in the presence of indicated concentrations ...
Matthew C. Egalka (6821846), Denise Evans (288201), Jayne Prats (5434199), Hairu Zhou (6821849), Ruizhi Li (844735), Jianchun Chen (465889), Thomas G. Diacovo (465888), Emile A. Bacha (6821855), Elisabeth A. Kaza (6821843), Julie A. Vincent (6821852), Scott L. Diamond (199884)   +10 more
core   +1 more source

The Use of Cangrelor in the Treatment of a Patient with COVID-19-Associated Acute Coronary Syndrome

Український журнал серцево-судинної хірургії, 2021
In December 2019, an outbreak of pneumonia caused by a novel coronavirus occurred in Wuhan, Hubei province, spreading rapidly first throughout China and subsequently across Europe, the United States (US), and the rest of the world.
S. V. Salo, O. V. Levchyshyna, A. Yu. Gavrylyshyn, A. K. Logutov, A. Yu. Hladun   +4 more
doaj   +1 more source

A Framework to Quantify Disparities in Pharmacogenomic Treatment Concordance and Drug Response Outcomes

Clinical and Translational Science, Volume 19, Issue 2, February 2026.
ABSTRACT Clinical PGx practice guidelines (PGx guidelines) may have limited generalizability for “marginalized” groups. We proposed the five‐step Real‐World Data for Genome‐Guided Prescribing (ReGGRx) framework and, using All of Us research program (AoU) data, examined its ability to estimate disparities in concordance with and benefit from PGx ...
Ilia Rattsev, James M. Stevenson, Casey Overby Taylor   +2 more
wiley   +1 more source